Literature DB >> 11748930

Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycine-alanine repeat.

M P Piechocki1, S A Pilon, C Kelly, W Z Wei.   

Abstract

ErbB-2 is ubiquitinated and degraded when dissociated from its membrane chaperone or bound by specific antibody. Reagents which induce such degradation have demonstrated antitumor activity and may impact ErbB-2 immunogenicity. To further understand ErbB-2 degradation and immunogenicity, a glycine-alanine repeat (GAr) or the reverse proline-alanine repeat (PAr) which protects certain proteins from proteasome degradation, was inserted after amino acid 5 (GAr5/PAr5) or 55 (GAr55/PAr55) of ErbB-2. When dissociated from the membrane with geldanamycin, E2-GAr5 and E2-PAr5 were not protected and still ubiquitinated and degraded by the proteasome, despite the presence of GAr. Insertional mutagenesis with GAr sequences at a.a. 55 of E2 enhanced proteasome degradation rendering E2-GAr55 and E2-PAr55 unstable on the membrane, but rescued in the cytosol by proteasome inhibitors. Immunization with E2-GAr induced antitumor immunity and CTL which lysed tumor cells expressing chimeric E2-GAr or wild-type E2 proteins, demonstrating efficient presentation through MHC I pathway. Improved understanding of the strong degradation signals in ErbB-2 may facilitate the development of anticancer agents or vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11748930     DOI: 10.1006/cimm.2001.1853

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  7 in total

1.  Gly-Ala repeats induce position- and substrate-specific regulation of 26 S proteasome-dependent partial processing.

Authors:  Chrysoula Daskalogianni; Sébastien Apcher; Marco M Candeias; Nadia Naski; Fabien Calvo; Robin Fåhraeus
Journal:  J Biol Chem       Date:  2008-08-29       Impact factor: 5.157

2.  Using an Agent-Based Model to Examine the Role of Dynamic Bacterial Virulence Potential in the Pathogenesis of Surgical Site Infection.

Authors:  Vissagan Gopalakrishnan; Moses Kim; Gary An
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-11       Impact factor: 4.730

3.  Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity.

Authors:  Jaina M Patel; Vincent F Vartabedian; Min-Chul Kim; Sara He; Sang-Moo Kang; Periasamy Selvaraj
Journal:  Biotechnol Bioeng       Date:  2015-04-17       Impact factor: 4.530

4.  Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth.

Authors:  Jaina M Patel; Vincent F Vartabedian; Erica N Bozeman; Brianne E Caoyonan; Sanjay Srivatsan; Christopher D Pack; Paulami Dey; Martin J D'Souza; Lily Yang; Periasamy Selvaraj
Journal:  Biomaterials       Date:  2015-09-28       Impact factor: 12.479

5.  Dendritic Cells Pulsed with Cytokine-Adjuvanted Tumor Membrane Vesicles Inhibit Tumor Growth in HER2-Positive and Triple Negative Breast Cancer Models.

Authors:  Luis E Munoz; Lenore Monterroza; Ramireddy Bommireddy; Yalda Shafizadeh; Christopher D Pack; Sampath Ramachandiran; Shaker J C Reddy; Periasamy Selvaraj
Journal:  Int J Mol Sci       Date:  2021-08-04       Impact factor: 5.923

6.  CD4+ and CD8+ T cells can act separately in tumour rejection after immunization with murine pneumotropic virus chimeric Her2/neu virus-like particles.

Authors:  Kalle Andreasson; Mathilda Eriksson; Karin Tegerstedt; Torbjörn Ramqvist; Tina Dalianis
Journal:  PLoS One       Date:  2010-07-19       Impact factor: 3.240

7.  The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity.

Authors:  Alexios Dimitriadis; Chrysanthi Gontinou; Constantin N Baxevanis; Avgi Mamalaki
Journal:  BMC Cancer       Date:  2009-10-30       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.